Cellares and GenomeFrontier Therapeutics entered a partnership to evaluate automated manufacturing for GenomeFrontier’s virus-free GF-CART01 using Cellares’ Cell Shuttle platform. The collaboration focuses on translating GenomeFrontier’s transfection unit process into an automated electroporator-based workflow for clinical development. The agreement is GenomeFrontier’s advance toward Phase I expansion in the U.S., while Cellares frames the deal as its first development collaboration in Asia. It targets a major bottleneck for autologous CAR T therapies: labor-intensive manufacturing with variability and scaling challenges. Cellares’ Cell Shuttle is positioned as end-to-end automated manufacturing aimed at improving scalability and reliability, supporting both clinical and future commercialization needs. For the field, the contract reinforces the shift toward automation-first manufacturing strategies that can stabilize process performance as CAR T programs move to broader patient access.